COG1 (Conserved Oligomeric Golgi Complex 1) encodes a core component of the COG complex, a heterotrimeric vesicle tethering complex essential for Golgi apparatus structure and function[1]. The COG complex coordinates intra-Golgi trafficking and maintains the proper localization of glycosylation enzymes, which are critical for proper protein modification and trafficking throughout the cell[2]. Mutations in COG1 cause Congenital Disorders of Glycosylation (CDG) type II, characterized by severe neurological involvement including developmental delay, seizures, and neurodegeneration[3].
| Attribute | Value |
|---|---|
| Gene Symbol | COG1 |
| Full Name | Conserved Oligomeric Golgi Complex 1 |
| Aliases | COG-1, LDLC |
| Chromosomal Location | 17q21.2 |
| NCBI Gene ID | 2274 |
| OMIM | 606978 |
| Ensembl ID | ENSG00000109805 |
| UniProt ID | Q8NHW3 |
The COG complex consists of eight subunits (COG1-8) organized into two subcomplexes: lobe A (COG1-4) and lobe B (COG5-8)[1:1]. COG1 serves as a scaffold protein that bridges interactions between other COG subunits and with downstream effectors.
COG1 interacts directly with COG2, COG3, and COG8, positioning it at the interface of both lobes[4]. This strategic location allows COG1 to coordinate the overall function of the complex.
The COG complex functions as a tethering factor that captures recycling vesicles from the endosomal system and other cellular compartments[2:1]:
Proper protein glycosylation is critical for neuronal function[7]:
COG function is essential for proper trafficking of lysosomal enzymes to lysosomes[8]:
COG1 mutations cause CDG-II, characterized by severe neurological involvement[3:2][9]:
Beyond inherited COG disorders, Golgi dysfunction is increasingly recognized in sporadic neurodegenerative diseases[10]:
The Golgi and ER form a continuous membrane network. COG dysfunction leads to:
Targeting COG-related pathways offers therapeutic potential[16]:
Wu X, et al. Conserved Oligomeric Golgi complex function in vesicle tethering. Journal of Cell Biology. 2004. ↩︎ ↩︎
Ungar D, et al. The COG complex in Golgi trafficking. Biochimica et Biophysica Acta. 2005. ↩︎ ↩︎ ↩︎
Foulquier F, et al. COG1 mutations cause congenital disorder of glycosylation type II. Human Molecular Genetics. 2006. ↩︎ ↩︎ ↩︎
Miller VJ, et al. Molecular architecture of the COG complex. Journal of Biological Chemistry. 2013. ↩︎ ↩︎
Hong W, et al. SNARE and COG function in Golgi trafficking. Cell. 2005. ↩︎
Rennolds J, et al. COG complex and SNARE assembly. Traffic. 2008. ↩︎
Scott H, et al. Glycosylation in neuronal development and function. Nature Reviews Neuroscience. 2014. ↩︎
ixin M, et al. COG and lysosomal enzyme trafficking. Molecular Biology of the Cell. 2010. ↩︎
Ng BG, et al. Spectrum of CDG phenotypes caused by COG mutations. Human Mutation. 2016. ↩︎
Gonatas NK, et al. Golgi fragmentation in neurodegenerative diseases. Brain Research Reviews. 2006. ↩︎
Sadat MA, et al. Golgi fragmentation in Alzheimer's disease. Acta Neuropathologica Communications. 2014. ↩︎
Fujita Y, et al. Golgi dysfunction in Parkinson's disease. Journal of Neural Transmission. 2018. ↩︎
Van Dis V, et al. Golgi fragmentation in ALS motor neurons. Neurobiology of Disease. 2014. ↩︎
Xu W, et al. ER stress in neurodegenerative disease. Nature Reviews Neurology. 2013. ↩︎
Nixon RA, et al. Autophagy in neurodegenerative disease. Nature Reviews Neurology. 2020. ↩︎
Iannuzzi C, et al. Therapeutic approaches to Golgi-related neurodegeneration. Current Opinion in Neurobiology. 2022. ↩︎